We use cookies to improve our service and to tailor our content and advertising to you. More info



Q



Home / Archive / Volume 67, Issue 8



Article menu



Gut microbiota Original article

PDF

Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice

Arno Hänninen^{1, 2}, Raine Toivonen¹, Sakari Pöysti¹, Clara Belzer³, Hubert Plovier⁴, Janneke P Ouwerkerk³, Rohini Emani¹, Patrice D Cani⁴, Willem M De Vos^{3, 5}

Author affiliations +

Abstract

Objective Intestinal microbiota is implicated in the pathogenesis of autoimmune type 1 diabetes in humans and in non-obese diabetic (NOD) mice, but evidence on its causality and on the role of individual microbiota members is limited. We investigated if different diabetes incidence in two NOD colonies was due to microbiota differences and aimed to identify individual microbiota members with potential significance.

Design We profiled intestinal microbiota between two NOD mouse colonies showing high or low diabetes incidence by 16S ribosomal RNA gene sequencing and colonised the high-incidence colony with the microbiota of the low-incidence colony. Based on unaltered incidence, we identified a few taxa which were not effectively transferred and thereafter, transferred experimentally one of these to test its potential significance.


Results Although the high-incidence colony adopted most microbial taxa present in the low-incidence colony, diabetes incidence remained unaltered. Among the few taxa which were not transferred, *Akkermansia muciniphila* was identified. As *A. muciniphila* abundancy is inversely correlated to the risk of developing type 1 diabetes-related autoantibodies, we transferred *A. muciniphila* experimentally to the

high-incidence colony. *A. muciniphila* transfer promoted mucus production and increased expression of antimicrobial peptide *Reg3y*, outcompeted *Ruminococcus torques* from the microbiota, lowered serum endotoxin levels and islet toll-like receptor expression, promoted regulatory immunity and delayed diabetes development.

Conclusion Transfer of the whole microbiota may not reduce diabetes incidence despite a major change in gut microbiota, but single symbionts such as *A. muciniphila* with beneficial metabolic and immune signalling effects may reduce diabetes incidence when administered as a probiotic.

http://dx.doi.org/10.1136/gutjnl-2017-314508

Statistics from Altmetric.com



BMJ Innovations

Keep up to date with the latest advances in medical innovation

Learn more today

BMJ

Linked Articles

Request Permissions

View Full Text

Footnotes

Contributors: AH and WMDV designed the work; AH analysed data and wrote the first version of the manuscript; RT, SAP, CB, HP, PDC, JPO and RE performed experiments and/or analysed data; WMDV and PDC reviewed the manuscript and wrote parts of the final version, which all authors approved.

Funding: This work was supported by Päivikki and Sakari Sohlberg Foundation (AH), Foundation for Diabetes Research Finland (AH), FRFS-WELBIO (WELBIO-CR-2012S-02R) (PDC), Funds Baillet Latour (PDC), European Commission (250172) (PDC), Horizon 2020 Framework Programme of European Research Council (336452) (PDC), H2020 Excellent Science and H2020 European Research Council (250172) (WMDV), Netherlands Organization for Scientific Research (024.002.002) (WMDV), Academy of Finland (1272870, 137389, 141140 (WMDV) and 285503 (AH)).

Competing interests: None declared.

Provenance and peer review: Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center's RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Request permissions

Copyright information: © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Linked Articles

Commentary

Does Akkermansia muciniphila play a role in type 1 diabetes?

Gilles Mithieux

Gut 2018; 67 1373-1374 Published Online First: 10 Feb 2018. doi: 10.1136/gutjnl-2017-315732

Read the full text or download the PDF:
Buy this article (\$37)
Subscribe
Log in



Consultant Gastrointestinal/Oncology Radiologist with a special interest in Peritoneal Malignancy

Basingstoke, Hampshire YC72 (£77,913 - £105,042)

We are looking for a replacement Consultant Radiologist with a GI or Oncology subspecialty interest to join a closely knit team

Recruiter: Hampshire Hospitals NHS Foundation Trust

Apply for this job

Consultant in Gastroenterology

Livingston, West Lothian | £80,653.00 to £107,170.00

Applications are welcome for the above permanent full time post working 40 hours per week post based at St John's Hospital, Livingston.

Recruiter: NHS Lothian

Apply for this job

Consultant Gastroenterology

Worcester, Worcestershire £77,913 - £105,042

The new appointee would have general luminal gastroenterology and endoscopy skills.

Recruiter: Worcestershire Acute Hospitals NHS Trust

Apply for this job

Consultant in Gastroenterology

Llantrisant, Pontyclun | £75,881 - £98,515

Other content recommended for you

Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease Christoph Grander et al., Gut

Does Akkermansia muciniphila play a role in type 1 diabetes?

Gilles Mithieux, Gut

Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology

Maria Carlota Dao et al., Gut

An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice

Na-Ri Shin et al., Gut

Microbiota and diabetes: an evolving relationship

Herbert Tilg et al., Gut

Enterococcus faecium NCIMB 10415 does not protect interleukin-10 knock-out mice from chronic gut inflammation

B. Ganesh et al., Beneficial Microbes

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

Maximilian J Hochmair, Future Oncology



CONTENT

Latest

Current issue

Archive

Browse by topic

Most read articles

Top cited articles

Responses

JOURNAL

About

Editorial board

Thank you to our reviewers

Sign up for email alerts

Subscribe

AUTHORS

Instructions for authors

Submit an article paper

Editorial policies

Open Access at BMJ

BMJ Author Hub

HELP

Contact us

Reprints

Permissions

Advertising

Feedback form













Website Terms & Conditions

Privacy & Cookies

Contact BMJ

Online: ISSN 1468-3288 Print: ISSN 0017-5749

Copyright © 2018 BMJ Publishing Group Ltd & British Society of Gastroenterology.

京ICP备15042040号-3

BMJ Innovations







Be the first to read the latest research



Sign up for email alerts >